reports
Invitation to the annual shareholders’ meeting
Invitation to the annual shareholders’ meeting The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and the Board of Directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 - December 31) of 2023. This equals a pay-out ratio of 53.2% of Novonesis’ adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a ...
Share-based legacy RSU program granted
Share-based legacy RSU program granted Share-based legacy RSU program granted Novonesis’ Board of Directors has following the merger with Chr. Hansen Holding A/S (“Chr. Hansen”) today approved the continuation in 2024 of a legacy Chr. Hansen annual short-term incentive program comprising of up to 125,000 restricted share units (RSUs) for around 130 legacy Chr. Hansen key employees below the Executive Management level. Receipt of the RSUs is subject to specified KPIs and criteria supporting performance and retention. The KPIs include personal targets and financial performance indi...
2024 outlook and pro forma financials
2024 outlook and pro forma financials Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis, said: “Today we provide key pro forma numbers as well as the first outlook for our new company. On a pro forma basis, 2023 was a solid year for Novonesis, including a Chr. Hansen that on a stand-alone basis delivered well in range of its latest full year outlook. We expect a solid 2024 performance with overall organic sales growth of 5-7% including growth across all subareas, and a ...
Novonesis will host a conference call regarding 2024 outlook and 2023 ...
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET. To join the live webcast, please click . To register and receive access details for the conference call, please click . Attachment
Resolutions from the Extraordinary Shareholders’ Meeting 2024
Resolutions from the Extraordinary Shareholders’ Meeting 2024 Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders’ meeting was conducted. The following resolutions were made: Adoption of Novonesis A/S as secondary name and amendment of the Articles of Association in accordance herewithElection of Jesper Brandgaard as Vice Chair of the Board of DirectorsElection of Lise Kaae, Kevin Lane and Kim Stratton as members of the Board of Directors Following the extraordinary shareholders’ meeting, the Board of Directors consists of the following members: Cornelis ...
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S An extraordinary shareholders’ meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark. Attachments
The Novozymes Report 2023
The Novozymes Report 2023 This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024. The new combined group is called Novonesis. As an annual report is required to cover the activities of a group during a financial year, this report only discloses Novozymes’ financial and non-financial performance in 2023. Non-financial elements concerning the combined group, Novonesis, are provided in separate and clearly labeled sections. Read more about Novonesis in the section The next step on our strategic journey. T...
Trading by management and close relations of management
Trading by management and close relations of management Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B. The Executive Leadership Team has on February 1st, 2024 from Novozymes A/S received the allocated shares from the incentive program for the period 2021-2023. An o...
Settlement of the combination of Novozymes and Chr. Hansen Holding suc...
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024Company announcement No. 07 On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination") was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024. As previously...
Legacy Novozymes delivers solid last full-year results
Legacy Novozymes delivers solid last full-year results Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality. COPENHAGEN, Denmark – February 1, 2024. In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROI...
Results update for 2023 – unaudited
Results update for 2023 – unaudited 6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation As Novozymes just closed the combination with Chr. Hansen on January 29, and the annual report now is expected to be released on February 8, this announcement only contains unaudited numbers. Full audited financial statements as well as non-financial numbers will be released with the annual report on February 8. This result update allows us to provide selected numbers for Novozymes standalone as early as possible. Ester Baiget, President & CEO: “...
Total number of voting rights and capital on January 31, 2024
Total number of voting rights and capital on January 31, 2024 Total number of voting rights and capital on January 31, 2024 January 31, 2024Company announcement No. 05 Referring to company announcement 02, on January 29, 2024, where Novozymes A/S ("Novozymes") announced the completion and final registration with the Danish Business Authority of the statutory merger between Novozymes and Chr. Hansen Holding A/S, the share capital has been increased by nominally DKK 374,597,292 from DKK 562,000,000 to DKK 936,597,292 through the issuance of a total of 187,298,646 new Novozymes...
Trading by management and close relations of management
Trading by management and close relations of management January 29, 2024Company announcement No. 04 Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B. Please read the full announcement in PDF. Attachment
Major shareholder announcement
Major shareholder announcement Major shareholder announcement January 29, 2024Company announcement No. 03 On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination"), was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024. Pursuant to Section 30 of the Danish Capital Markets Act, Novozymes hereby announces that Novo Nordisk Fonden has on i...
The combination of Novozymes and Chr. Hansen is now successfully compl...
The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already assisting companies around the world in meeting both busines...
- Rune Majlund Dahl
Novozymes (Hold, TP: DKK380.00) - The last stand-alone guidance
We expect Novozymes to reach the mid-point of its 2023 guidance for 4–6% organic sales growth (we forecast 5.0%) and 25–26% EBIT margin before special items (we forecast 25.5%). We believe investor focus will be on the 2024 organic sales growth guidance (we expect 3–6% YOY and a 25–26% EBIT margin), but we expect the combined entity (Novonesis) to issue new guidance upon completion of the merger. We have downgraded to HOLD (BUY), but raised our target price to DKK380 (350).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.